Mortality in psoriatic arthritis patients, changes over time, and the impact of COVID-19 : results from a multicenter Psoriatic Arthritis Registry (PsART-ID)
© 2023. The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR)..
BACKGROUND: This study aimed to assess the mortality of PsA before and during the COVID-19 pandemic.
METHODS: From the prospective, multicenter PsART-ID (Psoriatic Arthritis Registry-International Database), patients from Turkey were analyzed by linking the registry to the Turkish Cause of Death Registry. The outcome of interest was death from any cause, pre-pandemic (since the onset of registry-March 2014-March 2020), and during the pandemic (March 2020-May 2021). The crude mortality rate and standardized mortality ratio (SMR) were determined.
RESULTS: There were 1216 PsA patients with a follow-up of 7500 patient-years. Overall, 46 deaths (26 males) were observed. In the pre-pandemic period, SMR for PsA vs the general population was 0.95 (0.61-1.49), being higher in males [1.56 (0.92-2.63)] than females [0.62 (0.33-1.17)]. The crude mortality rate in PsA doubled during the pandemic (pre-pandemic crude mortality rate: 5.07 vs 10.76 during the pandemic) with a higher increase in females (2.9 vs 8.72) than males (9.07 vs 14.73).
CONCLUSION: The mortality in PsA was found similar to the general population in the pre-pandemic era. The mortality rates in PsA doubled during the pandemic. Whether PsA patients have more risk of mortality than the general population due to COVID-19 needs further studies. Key Points • Decrease in mortality in PsA might be expected with the more effective treatment options and better disease control. • A crude mortality rate is comparable to the general population and not increased until the pandemic. • Currently, there is a 2-fold increase in crude mortality rate possibly due to the COVID-19.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
Clinical rheumatology - 42(2023), 2 vom: 01. Feb., Seite 385-390 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Erden, Abdulsamet [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Completed 30.01.2023 Date Revised 02.02.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s10067-022-06492-6 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM351485813 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM351485813 | ||
| 003 | DE-627 | ||
| 005 | 20231226051459.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10067-022-06492-6 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1171.xml |
| 035 | |a (DE-627)NLM351485813 | ||
| 035 | |a (NLM)36637636 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Erden, Abdulsamet |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Mortality in psoriatic arthritis patients, changes over time, and the impact of COVID-19 |b results from a multicenter Psoriatic Arthritis Registry (PsART-ID) |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.01.2023 | ||
| 500 | |a Date Revised 02.02.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR). | ||
| 520 | |a BACKGROUND: This study aimed to assess the mortality of PsA before and during the COVID-19 pandemic | ||
| 520 | |a METHODS: From the prospective, multicenter PsART-ID (Psoriatic Arthritis Registry-International Database), patients from Turkey were analyzed by linking the registry to the Turkish Cause of Death Registry. The outcome of interest was death from any cause, pre-pandemic (since the onset of registry-March 2014-March 2020), and during the pandemic (March 2020-May 2021). The crude mortality rate and standardized mortality ratio (SMR) were determined | ||
| 520 | |a RESULTS: There were 1216 PsA patients with a follow-up of 7500 patient-years. Overall, 46 deaths (26 males) were observed. In the pre-pandemic period, SMR for PsA vs the general population was 0.95 (0.61-1.49), being higher in males [1.56 (0.92-2.63)] than females [0.62 (0.33-1.17)]. The crude mortality rate in PsA doubled during the pandemic (pre-pandemic crude mortality rate: 5.07 vs 10.76 during the pandemic) with a higher increase in females (2.9 vs 8.72) than males (9.07 vs 14.73) | ||
| 520 | |a CONCLUSION: The mortality in PsA was found similar to the general population in the pre-pandemic era. The mortality rates in PsA doubled during the pandemic. Whether PsA patients have more risk of mortality than the general population due to COVID-19 needs further studies. Key Points • Decrease in mortality in PsA might be expected with the more effective treatment options and better disease control. • A crude mortality rate is comparable to the general population and not increased until the pandemic. • Currently, there is a 2-fold increase in crude mortality rate possibly due to the COVID-19 | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Mortality | |
| 650 | 4 | |a Pandemic | |
| 650 | 4 | |a Psoriatic arthritis | |
| 700 | 1 | |a Ayan, Gizem |e verfasserin |4 aut | |
| 700 | 1 | |a Kilic, Levent |e verfasserin |4 aut | |
| 700 | 1 | |a Solmaz, Dilek |e verfasserin |4 aut | |
| 700 | 1 | |a Bakirci, Sibel |e verfasserin |4 aut | |
| 700 | 1 | |a Kimyon, Gezmis |e verfasserin |4 aut | |
| 700 | 1 | |a Günal, Esen Kasapoglu |e verfasserin |4 aut | |
| 700 | 1 | |a Dogru, Atalay |e verfasserin |4 aut | |
| 700 | 1 | |a Bayindir, Ozun |e verfasserin |4 aut | |
| 700 | 1 | |a Dalkilic, Ediz |e verfasserin |4 aut | |
| 700 | 1 | |a Özisler, Cem |e verfasserin |4 aut | |
| 700 | 1 | |a Akar, Servet |e verfasserin |4 aut | |
| 700 | 1 | |a Cetin, Gözde Yildirim |e verfasserin |4 aut | |
| 700 | 1 | |a Tarhan, Emine Figen |e verfasserin |4 aut | |
| 700 | 1 | |a Küçüksahin, Orhan |e verfasserin |4 aut | |
| 700 | 1 | |a Omma, Ahmet |e verfasserin |4 aut | |
| 700 | 1 | |a Gonullu, Emel |e verfasserin |4 aut | |
| 700 | 1 | |a Yildiz, Fatih |e verfasserin |4 aut | |
| 700 | 1 | |a Ersozlu, Emine Duygu |e verfasserin |4 aut | |
| 700 | 1 | |a Cinar, Muhammed |e verfasserin |4 aut | |
| 700 | 1 | |a Tufan, Abdurrahman |e verfasserin |4 aut | |
| 700 | 1 | |a Pehlevan, Seval |e verfasserin |4 aut | |
| 700 | 1 | |a Esmen, Serpil Ergulu |e verfasserin |4 aut | |
| 700 | 1 | |a Yilmaz, Sema |e verfasserin |4 aut | |
| 700 | 1 | |a Duruoz, Tuncay |e verfasserin |4 aut | |
| 700 | 1 | |a Kasifoglu, Timucin |e verfasserin |4 aut | |
| 700 | 1 | |a Yazısız, Veli |e verfasserin |4 aut | |
| 700 | 1 | |a Aksu, Kenan |e verfasserin |4 aut | |
| 700 | 1 | |a Aydin, Sibel Zehra |e verfasserin |4 aut | |
| 700 | 1 | |a Kalyoncu, Umut |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical rheumatology |d 1987 |g 42(2023), 2 vom: 01. Feb., Seite 385-390 |w (DE-627)NLM012613037 |x 1434-9949 |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2023 |g number:2 |g day:01 |g month:02 |g pages:385-390 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s10067-022-06492-6 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2023 |e 2 |b 01 |c 02 |h 385-390 | ||